首页> 美国卫生研究院文献>Indian Journal of Hematology Blood Transfusion >Risk Factors Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant
【2h】

Risk Factors Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant

机译:异基因干细胞移植的急性白血病患者急性移植物抗宿主病的危险因素模式和临床结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We sought to determine risk factors, pattern and outcome of acute graft versus host disease (aGVHD) in seventy-seven acute leukemia patients who underwent allogeneic stem cell transplant at our centre from January 2008 to March 2013. GVHD prophylaxis with cyclosporine-methotrexate or cyclosporine-mycophenolate mofetil was used. Patients were divided in 2 groups, grade II-IV aGVHD (group A) and grade 0-I aGVHD (group B). Incidence of any grade and grade II-IV aGVHD was 44 and 18 %, respectively. The most common site of aGVHD was gastro-intestinal tract (65 %) followed by skin (35 %). Higher total nucleated cell (TNC) dose infused was associated with increased incidence of grade II-IV aGVHD. Incidence of relapse and incidence of slippage of chimerism was 21 and 36 % in group A while 37 and 27 % in group B respectively. Transplant related mortality (TRM) was 21 % in group A and 13 % in group B. Probability of OS and RFS at 4 years was 63 and 34 % in group A compared with 40 and 38 % in group B, respectively. We conclude that higher TNC dose infused is a risk factor for grade II-IV aGVHD with gut being the commonest site. Grade II-IV aGVHD did not have a significant impact on incidence of relapse, TRM and OS.
机译:我们试图确定自2008年1月至2013年3月在我中心接受异基因干细胞移植的77例急性白血病患者的急性移植物抗宿主病(aGVHD)的危险因素,模式和结果。环孢素-甲氨蝶呤或环孢菌素对GVHD的预防使用了麦考酚酯。将患者分为2组,II-IV级aGVHD(A组)和0-I aGVHD级(B组)。任何II级和IV级aGVHD的发生率分别为44%和18%。 aGVHD最常见的部位是胃肠道(65%),其次是皮肤(35%)。较高的总有核细胞(TNC)剂量与II-IV级aGVHD发生率增加相关。 A组复发率和嵌合率滑移率分别为21%和36%,而B组分别为37%和27%。 A组的移植相关死亡率(TRM)为21%,B组为13%.A组4年OS和RFS的概率分别为63%和34%,而B组分别为40%和38%。我们得出的结论是,较高的TNC剂量是II-IV级aGVHD的危险因素,肠道是最常见的部位。 II-IV级aGVHD对复发,TRM和OS的发生率没有显着影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号